keyword
MENU ▼
Read by QxMD icon Read
search

Alopecia chemotherapy

keyword
https://www.readbyqxmd.com/read/30098079/chemotherapy-induced-alopecia-the-urgent-need-for-treatment-options
#1
M Sikora, L Rudnicka
The paper of Shah et al. features a comprehensive review of scalp hyperthermia for chemotherapy-induced alopecia (CIA). Hair loss is psychologically devastating side effects of cytotoxic drugs and molecularly targeted agents. Although the majority of CIA is reversible, the psychological impact is so profound that may lead to refusal of therapy in up to 8% of patients. This article is protected by copyright. All rights reserved.
August 11, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/30087568/comparable-efficacy-and-less-toxicity-of-pegylated-liposomal-doxorubicin-versus-epirubicin-for-neoadjuvant-chemotherapy-of-breast-cancer-a-case-control-study
#2
Minjun Dong, Liang Luo, Xiaogang Ying, Xianqiu Lu, Jianguo Shen, Zhinong Jiang, Linbo Wang
Background: Pegylated liposomal doxorubicin (PLD) and epirubicin are both superior variants of doxorubicin and are commonly applied as basic chemotherapeutics in breast cancer. However, the direct comparison of their efficacy and side effects has not been adequately reported. This study aimed to compare the efficacy and toxicity of PLD and epirubicin as neoadjuvant chemotherapy for invasive breast cancer. Patients and methods: Women (n = 43) with invasive breast cancer who received neoadjuvant chemotherapy with the regimens containing PLD (PLD group) were analyzed and 1:2 matched with those (n = 86) who received regimens containing epirubicin (epirubicin group) according to clinical TNM staging and taxane combination...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/30048865/efficacy-of-scalp-cooling-in-reducing-alopecia-in-early-breast-cancer-patients-receiving-contemporary-chemotherapy-regimens
#3
Arlene Chan, Astrid Bauwens, Sally Pontre, Sally Jackson, Frances McGlone, Tracie Ernenwein, Jun Chih, Christopher Reid
INTRODUCTION: Hair loss as a result of chemotherapy for early breast cancer (EBC) is a frequent and distressing side effect. Minimising hair loss may improve mood and body image. Our aim was to determine scalp cooling (SC) efficacy in EBC patients receiving contemporary chemotherapy regimen, to inform future patients choice to use SC or not. METHODS AND RESULTS: Prospective cohort study of 60 stage 1-3 EBC patients recommended to receive taxane or anthracycline-taxane chemotherapy regimens...
July 18, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30036863/long-term-response-with-eribulin-mesylate-in-a-breast-cancer-patient-a-case-report
#4
Marta Medici, Emanuela Fossile
Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain experienced before the initiation of eribulin...
2018: Oncology
https://www.readbyqxmd.com/read/30001151/the-dignicap-scalp-cooling-system-and-its-use-in-the-treatment-of-chemotherapy-induced-alopecia
#5
Mollie M Mustoe, Carmen M Lee, Michelle E Melisko, Laura J Esserman, Hope S Rugo
Chemotherapy-induced alopecia remains an emotionally traumatic side effect for cancer patients that impacts the quality of life, may be protracted in duration and may influence treatment decisions. Scalp cooling has been shown to be effective in preventing chemotherapy-induced alopecia. The DigniCap Scalp Cooling System is designed to prevent hair loss by cooling the scalp to reduce the impact of chemotherapy on hair follicle cells. Recent studies have shown the safety, efficacy and low-grade toxicity of the DigniCap System with a 66...
July 12, 2018: Future Oncology
https://www.readbyqxmd.com/read/29992733/monitoring-chemotherapy-induced-alopecia-with-trichoscopy
#6
Alfredo Rossi, Maria Caterina Fortuna, Gemma Caro, Michele Cardone, Valentina Garelli, Sara Grassi, Marta Carlesimo
BACKGROUND: Chemotherapy-induced alopecia (CIA) ranks among the psychologically most devastating effects of cancer treatment for oncological patients, with an overall incidence of 65%. Nowadays trichoscopy is largely employed in the diagnosis of alopecia, but no description of CIA trichoscopic pattern is present in literature. AIMS: We want to create an organic description of CIA trichoscopic aspects. METHODS: Oncological patients candidate to chemotherapy drugs, afferent to our trichological outpatient were studied...
July 11, 2018: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/29991956/clinical-efficacy-and-safety-of-aidi-injection-plus-docetaxel-based-chemotherapy-in-advanced-nonsmall-cell-lung-cancer-a-meta-analysis-of-36-randomized-controlled-trials
#7
Zheng Xiao, Chengqiong Wang, Lianhong Li, Xuemei Tang, Nana Li, Jing Li, Ling Chen, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Background. Aidi injection is an important adjuvant anticancer drug commonly used in China. Can Aidi injection plus docetaxel-based chemotherapy improve clinical efficacy with good safety in NSCLC? To further reveal its clinical effectiveness, we systematically evaluated all the related studies. Method. We collected all the studies about Aidi injection plus docetaxel-based chemotherapy for NSCLC on Medline, Embase, Web of Science, CNKI, VIP, Wanfang, CBM, CENTRAL, Chi-CTR, and US-clinical trials. We evaluated their methodological bias risk according to the Cochrane evaluation handbook (5...
2018: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29983677/toxic-epidermal-necrolysis-in-a-female-with-metastatic-breast-cancer-treated-with-vinorelbine
#8
A Bazine, M Fetohi, T Namad, J El Benaye, M A Ennouhi, T Mahfoud, M Ichou
Vinorelbine is an anticancer agent with high clinical efficacy for the treatment of metastatic breast cancer. Toxic epidermal necrolysis is a rare but serious cutaneous adverse reaction associated with drug therapy. We hereby present a case report of a patient with metastatic breast cancer, treated with vinorelbine, who developed toxic epidermal necrolysis. To the best of our knowledge, ours is the second case report describing this exceptional dermatologic emergency associated with vinorelbine. In June 2014, a 33-year-old female was treated for localized breast cancer...
December 31, 2017: Annals of Burns and Fire Disasters
https://www.readbyqxmd.com/read/29961278/-ema-co-regimen-for-chemotherapy-24-patients-with-ultra-high-risk-gestational-trophoblastic-neoplasia
#9
T Shen, L L Chen, J L Qin, X Y Wang, X D Cheng, X Xie, W G Lyu
Objective: To evaluate etoposide, methotrexate and dactinomycin (EMA) /cyclophosphamide and vincristine (CO) regimen for treatment of ultra high-risk gestational trophoblastic neoplasia (GTN) . Methods: A total of twenty-four ultra high-risk patients who had International Federation of Gynecology and Obstetrics (FIGO) prognostic scores greater or equal to 12 with liver, brain, or extensive metastases did poorly when treated with primary chemotherapy admitted in Women ' s Hospital, School of Medicine, Zhejiang University from January 2001 to December 2015...
June 25, 2018: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/29946791/chemotherapy-drug-concentrations-in-hair-follicles-a-potential-biomarker-to-monitor-the-effectiveness-of-scalp-cooling-for-chemotherapy-induced-alopecia
#10
Jung-Woo Chae, Raymond Ng, Alexandre Chan
No abstract text is available yet for this article.
June 26, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29925345/induction-therapy-with-paclitaxel-and-bevacizumab-followed-by-switch-maintenance-therapy-with-eribulin-in-japanese-patients-with-her2-negative-metastatic-breast-cancer-a-multicenter-collaborative-open-label-phase-ii-clinical-study-for-the-sbccsg-35-investigators
#11
Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka, Masafumi Kurosumi
BACKGROUND: To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). METHODS: Patients, who had previously undergone a maximum of 2 regimens of chemotherapy, received 3 cycles of induction therapy with paclitaxel (90 mg/m2 intravenously on days 1, 8, and 15 followed by 1-week drug holiday) and bevacizumab (10 mg/kg intravenously after the completion of paclitaxel administration on days 1 and 15)...
June 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29923063/persistent-major-alopecia-following-adjuvant-docetaxel-for-breast-cancer-incidence-characteristics-and-prevention-with-scalp-cooling
#12
M Martín, J C de la Torre-Montero, S López-Tarruella, K Pinilla, A Casado, S Fernandez, Y Jerez, J Puente, I Palomero, R González Del Val, M Del Monte-Millan, T Massarrah, C Vila, B García-Paredes, J A García-Sáenz, A Lluch
BACKGROUND: Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. PATIENTS AND METHODS: BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1...
June 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29920955/nimotuzumab-combined-with-chemotherapy-as-first-line-treatment-for-advanced-lung-squamous-cell-carcinoma
#13
Xiaoyan Si, Shafei Wu, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Xuan Zeng, Li Zhang
BACKGROUND: This study was conducted to evaluate the efficacy and safety of nimotuzumab combined with chemotherapy as first-line therapy in advanced lung squamous cell carcinoma (LSCC), and to explore predictive biomarkers of the efficacy of nimotuzumab. METHODS: A retrospective study was conducted of patients with advanced LSCC administered nimotuzumab combined with chemotherapy as first-line therapy from June 2012 to December 2016 at the Department of Respiratory Medicine, Peking Union Medical College Hospital...
June 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29858027/osimertinib-compared-docetaxel-bevacizumab-as-third-line-treatment-in-egfr-t790m-mutated-non-small-cell-lung-cancer
#14
Keke Nie, Zhongfa Zhang, Chunling Zhang, Chuanxin Geng, Ling Zhang, Xiajuan Xu, Shichao Liu, Songping Wang, Xingjun Zhuang, Ketao Lan, Youxin Ji
OBJECTIVE: To compare the efficacy and toxicity of osimertinib versus docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated NSCLC. METHODS: In this phase 3, open-label, three-center study, we randomly assigned (1:1) previously treated with TKI-chemotherapy or chemotherapy-TKI recurrent or metastatic advanced non-squamous lung cancer patients into two groups. These patients had acquired EGFR T790M resistance mutation confirmed by tumor tissues or serum...
July 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29849714/the-traditional-chinese-medicine-kangai-injection-as-an-adjuvant-method-in-combination-with-chemotherapy-for-the-treatment-of-breast-cancer-in-chinese-patients-a-meta-analysis
#15
REVIEW
Jing-Xian Xue, Zhi-Yuan Zhu, Wei-He Bian, Chang Yao
Objective: The traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy has been widely used for treating breast cancer in clinical practice in China. This study systematically reviewed the clinical effect and safety of traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy for treating Chinese patients with breast cancer. Methods: Seven databases were searched in this study, namely, PubMed, the Cochrane Library, Embase, CNKI, Sino Med, VIP, and Wanfang Data...
2018: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29743140/a-phase-i-single-arm-open-label-dose-escalation-study-of-intraperitoneal-cisplatin-and-doxorubicin-in-patients-with-recurrent-ovarian-cancer-and-peritoneal-carcinomatosis
#16
Clemens B Tempfer, Urs Giger-Pabst, Veronika Seebacher, Miriam Petersen, Askin Dogan, Günther A Rezniczek
OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2 , cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis...
July 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29706375/balixafortide-plus-eribulin-in-her2-negative-metastatic-breast-cancer-a-phase-1-single-arm-dose-escalation-trial
#17
Sonia Pernas, Miguel Martin, Peter A Kaufman, Marta Gil-Martin, Patricia Gomez Pardo, Sara Lopez-Tarruella, Luis Manso, Eva Ciruelos, Jose Alejandro Perez-Fidalgo, Cristina Hernando, Foluso O Ademuyiwa, Katherine Weilbaecher, Ingrid Mayer, Timothy J Pluard, Maria Martinez Garcia, Linda Vahdat, Jose Perez-Garcia, Achim Wach, Debra Barker, Samson Fung, Barbara Romagnoli, Javier Cortes
BACKGROUND: The C-X-C chemokine receptor type 4 (CXCR4)-stromal cell-derived factor-1α (SDF-1α) axis regulates function and trafficking of immune cells and the tumour microenvironment. CXCR4 antagonists have been shown to enhance the activity of different anticancer treatments in preclinical models. We assessed the safety, tolerability, pharmacokinetics, and preliminary phase 1 activity of the CXCR4 antagonist, balixafortide, in combination with eribulin chemotherapy in patients with heavily pretreated, relapsed metastatic breast cancer...
June 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29660543/scalp-cooling-successfully-prevents-alopecia-in-breast-cancer-patients-undergoing-anthracycline-taxane-based-chemotherapy
#18
Ines Vasconcelos, Alexandra Wiesske, Winfried Schoenegg
INTRODUCTION: Chemotherapy for breast cancer induces alopecia, representing a major source of patient distress. This study assesses whether a scalp-cooling device is effective in reducing chemotherapy-induced alopecia, and assesses adverse treatment effects. MATERIALS AND METHODS: A prospective observational study including women with breast cancer undergoing chemotherapy and scalp cooling using a Paxman device. The primary efficacy end points were: successful hair preservation (no hair loss; <30% hair loss not requiring a wig; or <50% hair loss not requiring a wig) at the completion of chemotherapy...
August 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29660423/cme-part-2-hair-disorders-in-cancer-survivors-persistent-chemotherapy-induced-alopecia-persistent-radiotherapy-induced-alopecia-and-hair-growth-disorders-related-to-endocrine-therapy-or-cancer-surgery
#19
REVIEW
Azael Freites-Martinez, Jerry Shapiro, Corina van den Hurk, Shari Goldfarb, Joaquin Jimenez, Anthony M Rossi, Ralf Paus, Mario E Lacouture
With increasing survival rates across all cancers, survivors represent a growing population that is frequently affected by persistent or permanent hair growth disorders as a result of systemic therapies, radiotherapy, surgical procedures, and therapeutic transplants. These hair disorders include persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, endocrine therapy-induced alopecia and hirsutism, post-surgery alopecia and localized hypertrichosis, alopecia attributed to therapeutic transplants, and to novel anticancer therapies...
April 13, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29660422/cme-part-1-hair-disorders-in-cancer-patients
#20
REVIEW
Azael Freites-Martinez, Jerry Shapiro, Shari Goldfarb, Julie Nangia, Joaquin J Jimenez, Ralf Paus, Mario E Lacouture
Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders (including alopecia, hirsutism, hypertrichosis, pigmentary and textural hair changes). The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy -induced alopecia has been well-documented mainly in the oncology literature, however the effect of other alterations such as radiation-induced alopecia, hirsutism, changes in hair color or texture on quality of life have not been described...
April 13, 2018: Journal of the American Academy of Dermatology
keyword
keyword
158578
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"